Occam Places Aron Feingold as VP of Investor Relations & Corporate Communications at Geron
_410x328.jpg)
Geron is a public, clinical stage biotech company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, with disease modification potential for myeloid hematologic malignancies.
In early 2022, Occam placed Aron Feingold (former Sangamo and Pfizer), as VP of Investor Relations & Corporate Communications, a role crucial to Geron at this point in its evolution, as it approaches potential registration and commercialization.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.